Trulieve Cannabis (TRLV) and The Competition Critical Comparison

Trulieve Cannabis (NYSE:TRLV) is one of 898 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Trulieve Cannabis to similar businesses based on the strength of its risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Trulieve Cannabis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
Trulieve Cannabis Competitors	-2,378.15%	-221.75%	-16.00%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Trulieve Cannabis and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1	1	1	0	2.00
Trulieve Cannabis Competitors	7754	13795	25598	1026	2.41

Trulieve Cannabis currently has a consensus price target of $15.00, suggesting a potential upside of 49.78%. As a group, “Pharmaceuticals” companies have a potential upside of 35.61%. Given Trulieve Cannabis’ higher probable upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than its peers.

Valuation & Earnings

This table compares Trulieve Cannabis and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Trulieve Cannabis	$1.18 billion	-$116.38 million	91.05
Trulieve Cannabis Competitors	$3.65 billion	$3.21 billion	548.15

Trulieve Cannabis’ peers have higher revenue and earnings than Trulieve Cannabis. Trulieve Cannabis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Trulieve Cannabis peers beat Trulieve Cannabis on 8 of the 12 factors compared.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.